Altre lingue Zymeworks Inc.

Azioni

ZYME

US98985Y1082

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
8,55 ^USD	-0,12%		-3,39%	-17,71%

08/04	Zymeworks Inc. presenta i nuovi dati di diversi programmi di sviluppo preclinico al Meeting Annuale 2024 dell'Associazione Americana per la Ricerca sul Cancro	CI
04/04	Zymeworks Inc. rimuove il Dr. Christopher Astle dalla posizione di Vicepresidente senior	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	20/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	12/04
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024	11/04
Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	08/04
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting	08/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	05/04
Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	04/04
Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President	04/04
Zymeworks Inc. Announces the Composition of the Committees	28/03
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors	28/03
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024	28/03
Zymeworks Announces Participation in Upcoming Investor Conferences	27/03
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results	06/03
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	05/03
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	05/03
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	05/03
Zymeworks Announces Participation in Upcoming Investor Conferences	27/02
Zymeworks Announces Participation in Upcoming Investor Conferences	27/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Zymeworks Inc.

Azioni

ZYME

US98985Y1082

Altre lingue

Filtri